Encouraging results from Ipsen's GuidAge study of EGb 761 in the prevention of Alzheimer's dementia

23 June 2010

French drugmaker Ipsen has released top-line results of GuidAge, the longest (five years) and largest (2,854 subjects) European study in the prevention of Alzheimer's dementia (AD). The aim of this study was to assess the efficacy of a 5-year treatment with EGb 761 in the prevention of AD in a population of elderly aged 70 or more, with memory complaint spontaneously expressed to their family physician and who lived at home at the inclusion in the study.

1. Primary efficacy objective (to delay conversion to Alzheimer's Dementia):

There were significant difference not statistically observed in the overall study population: during the study, 134 individuals developed AD, including 61 patients (4.3%) in the EGb 761® group and 73 patients (5.2%) in the placebo group (p=0.31).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK